Review Article
Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases
Table 1
FDA-approved epigenetic drugs.
| Drug | Epigenetic effect | Clinical trial |
| Miravirsen | Neutralisation of miRNA-122 | Phase II [13] | MRX34 | Ectopic expression of miRNA-34 | Phase I [9] | Azacitidine (Vidaza) | DNA methyltransferase inhibitor | Phase III [15] | Decitabine (Dacogen) | DNA methyltransferase inhibitor | Phase III [17] | Vorinostat (Zolinza) | Pan-HDAC inhibitor | Phase II [24] |
|
|